x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230571
| Product Information | |
|---|---|
| CAS No. | 76541-72-5 |
| Synonyms | SR-202 |
| Formula | C11H17ClO7P2 |
| Molecular Weight | 358.65 |
| Product Description | Mifobate (SR-202) is a potent and specific PPARγ antagonist. Mifobate (SR-202) selectively inhibits Thiazolidinedione (TZD)-induced PPARγ transcriptional activity (IC50=140 μM). Mifobate (SR-202) does not affect basal or ligand-stimulated transcriptional activity of PPARα, PPARβ, or the farnesoid X receptor (FXR). Mifobate (SR-202) shows antiobesity and antidiabetic effects. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 99% |
| Shipping | Shipped on dry ice. |
| Storage | Protect from light. Powder: -80 °C, 2 years; -20 °C, 1 year. In solvent: -80 °C, 6 months; -20 °C, 1 month (protect from light). |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
